KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Net Income (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Net Income for 17 consecutive years, with $206.0 million as the latest value for Q1 2026.

  • For Q1 2026, Net Income rose 1228.66% year-over-year to $206.0 million; the TTM value through Mar 2026 reached $543.9 million, up 336.01%, while the annual FY2025 figure was $313.7 million, 212.79% up from the prior year.
  • Net Income hit $206.0 million in Q1 2026 for Alnylam Pharmaceuticals, up from $111.5 million in the prior quarter.
  • Across five years, Net Income topped out at $292.7 million in Q3 2025 and bottomed at -$405.9 million in Q3 2022.
  • Average Net Income over 5 years is -$77.9 million, with a median of -$83.8 million recorded in 2024.
  • Year-over-year, Net Income plummeted 292.43% in 2025 and then skyrocketed 1228.66% in 2026.
  • Alnylam Pharmaceuticals' Net Income stood at -$207.5 million in 2022, then surged by 33.55% to -$137.9 million in 2023, then surged by 39.24% to -$83.8 million in 2024, then soared by 233.17% to $111.5 million in 2025, then soared by 84.67% to $206.0 million in 2026.
  • According to Business Quant data, Net Income over the past three periods came in at $206.0 million, $111.5 million, and $292.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.